Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

• Revenue in USD (TTM)47.00k
• Net income in USD-46.47m
• Incorporated2014
• Employees23.00

• Location
  Checkpoint Therapeutics Inc95 SAWYER ROAD, SUITE 110WALTHAM 02453United StatesUSA
• Phone+1 (781) 652-4500
• Fax+1 (302) 531-3150
• Websitehttps://checkpointtx.com/